ALMIRALL : Daniel Martínez Carretero, appointed Chief Financial Officer (CFO) of Almirall
June 02, 2011 at 04:30 am EDT
By
Share
Barcelona, 1 June 2011.- Following the announcement of the appointment of Eduardo Sanchiz as Chief Executive Officer, Almirall communicates the appointment of Daniel Martínez Carretero as Chief Financial Officer (CFO) also effective as of 1 July 2011. In addition to Finance, Daniel will also be heading the areas of Purchasing, Information Systems (IT) and Investor Relations.
Daniel Martínez brings a solid professional trajectory to this role. He has a degree in Economics and a Master's in Finance Management from EADA.
He joined Almirall in September 2008 as Deputy CFO reporting to Eduardo Sanchiz, then Director of Corporate Development and Finance. During this period Daniel Martínez has led the finance area jointly with Eduardo Sanchiz and has been responsible for various organisational and finance projects as well as being a member of the Management Board.
Prior to joiningAlmirall he spent several years in PepsiCo in a variety of roles in the finance area, finally holding the position of Finance Director Iberia. After PepsiCo, Daniel continued his career in Reckitt Benckiser as Finance Director for South West Europe.
Almirall is an international pharmaceutical company based on innovation and committed to health. Headquartered in Barcelona, Spain, it researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing.
Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), gastrointestinal disorders, psoriasis and other dermatological conditions.
Almirall's products are currently present in over 70 countries while it has direct presence in Europe and Latin America through 12 affiliates.
Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.
ALMIRALL, S.A. 
